文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

完全切除脑转移瘤术后25Gy/5次分次立体定向放疗的单中心回顾性研究

Postoperative fractionated stereotactic radiotherapy for completely resected brain metastases with 25 Gy in five fractions: A single-center retrospective study.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-05-26

该单中心回顾性研究纳入2017至2025年间接受术后fSRT的159例完全切除脑转移瘤患者(181个切除腔),统一处方25Gy/5次至80%等剂量线。12和48个月局部控制率分别为91.8%和89.4%,症状性放射性坏死发生率3.2%,中位OS为31个月,中位iPFS为20个月。

要点

  • 25Gy/5次术后fSRT的48个月局部控制率达89.4%,症状性放射性坏死仅3.2%
  • 中位OS 31个月,中位iPFS 20个月
  • 颅外疾病未控是OS较差的唯一独立预测因素(HR 2.58,p<0.001)

核心结论

  • 术后fSRT 25Gy/5次处方至80%等剂量线安全、耐受良好,并在肿瘤手术切除后提供持久局部控制。

研究设计与样本

  • 单中心回顾性研究,纳入2017至2025年间接受术后fSRT的完全切除脑转移瘤患者,共159例、181个切除腔。
  • 所有患者接受25Gy/5次,处方至80%等剂量线,PTV为切除腔加2mm外扩。
  • 主要终点为局部控制和无症状性放射性坏死,次要终点包括OS和iPFS;采用Kaplan-Meier法估计生存,Cox回归分析预后因素。

主要发现

  • 中位PTV为22.3 cc,中位CTV为13.8 cc,中位随访48个月。
  • 12和48个月局部控制率分别为91.8%和89.4%。
  • 症状性放射性坏死发生率为3.2%。
  • 中位OS为31个月,中位iPFS为20个月。
  • 多因素分析中,颅外疾病未控是OS较差的唯一独立预测因素(HR 2.58,p<0.001)。

关键数值与推荐

  • 术后fSRT处方剂量为25Gy分5次,处方至80%等剂量线,PTV为切除腔加2mm外扩。

临床怎么用

  • 对于完全切除的脑转移瘤,术后采用25Gy/5次fSRT至80%等剂量线可作为安全且局部控制持久的治疗选择。
  • 颅外疾病未控患者OS较差,提示需关注颅外疾病管理。

局限性

  • 本研究为单中心回顾性研究,证据等级有限,需等待正在进行的3期试验提供更多证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Brain metastases (BM) occur in up to 40% of patients with solid tumors. Following surgical resection, postoperative radiotherapy to the resection cavity is standard of care, yet optimal dose prescription and fractionation remain uncertain. This study evaluates clinical outcomes and toxicity of a standardized postoperative fractionated stereotactic radiotherapy (fSRT) regimen. MATERIALS AND METHODS: This retrospective single-center study included patients treated between 2017 and 2025 with postoperative fSRT for completely resected brain metastases. All patients received 25 Gy in five fractions, prescribed to the 80% isodose line. The planning target volume (PTV) was defined as the resection cavity plus a 2-mm margin. Primary endpoints were local control (LC) and symptomatic radiation necrosis. Secondary endpoints included overall survival (OS) and intracranial progression-free survival (iPFS). Survival outcomes were estimated using the Kaplan-Meier method, and Cox regression analyses were performed to identify prognostic factors. RESULTS: A total of 159 patients and 181 resection cavities were analyzed. The median PTV was 22.3 cc, while the median clinical target volume (CTV) measured 13.8 cc. Median follow-up was 48 months. Local control rates at 12 and 48 months were 91.8% and 89.4%, respectively. Symptomatic radiation necrosis occurred in 3.2% of patients. Median OS was 31 months, and median iPFS was 20 months. In multivariable analysis, uncontrolled extracranial disease was the only independent predictor of inferior OS (hazard ratio 2.58, p < 0.001). CONCLUSION: Postoperative fSRT with 5 × 5 Gy prescribed to the 80% isodose line is safe, well-tolerated, and provides durable local control after surgical tumor removal. Additional evidence is eagerly anticipated from the ongoing phase 3 trials. TRIAL REGISTRATION: The local ethical review committee of Ludwig-Maximilians-University Munich (application number: 24-0206) approved this study. The study has been officially registered on the German Clinical Trials Register (DRKS00034150) on December 20, 2024.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Maier SH, Nitschmann A, Dehelean DC, et al. Postoperative fractionated stereotactic radiotherapy for completely resected brain metastases with 25 Gy in five fractions: A single-center retrospective study. Clin Transl Radiat Oncol. 2026. PMID: 42255983. doi:10.1016/j.ctro.2026.101198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。